Inicio>>Signaling Pathways>> Proteases>> Tyrosinases>>XMD16-5

XMD16-5

Catalog No.GC19385

XMD16-5 es un potente inhibidor de TNK2 con valores IC50 de 16 y 77 nM para las mutaciones D163E y R806Q, respectivamente.

Products are for research use only. Not for human use. We do not sell to patients.

XMD16-5 Chemical Structure

Cas No.: 1345098-78-3

Tamaño Precio Disponibilidad Cantidad
5mg
74,00 $
Disponible
10mg
131,00 $
Disponible
25mg
265,00 $
Disponible
50mg
455,00 $
Disponible
100mg
803,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com


Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

XMD16-5 is a potent TNK2 inhibitor with IC50 values of 16 and 77 nM for the D163E and R806Q mutations, respectively.

XMD16-5 potently inhibits the growth of the TNK2 mutant expressing cell lines while having little or no effect on the control cells out to the highest tested concentrations (1,000 nM). XMD16-5 has IC50s of 16 nM and 77 nM for the D163E and R806Q mutations. The effects of XMD16-5 on TNK2 cell lines are largely due to on-target effects on TNK2. Auto-phosphorylation of overexpressed TNK2 mutants could be blocked with TNK2 inhibitor XMD16-5[1].

References:
[1]. Maxson JE, et al. Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis.

Reseñas

Review for XMD16-5

Average Rating: 5 ★★★★★ (Based on Reviews and 34 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for XMD16-5

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.